AL unit dose age specific pre-packs — Competitive Intelligence Brief

AL unit dose age specific pre-packs (AL unit dose age specific pre-packs) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artemisinin-based combination therapy (ACT). Area: Infectious Disease / Parasitology.

phase 3 Artemisinin-based combination therapy (ACT) Parasite hemoglobin metabolism; mitochondrial electron transport Infectious Disease / Parasitology Small molecule

Target snapshot

AL unit dose age specific pre-packs (AL unit dose age specific pre-packs) — Malaria Consortium, Uganda. AL (artemether-lumefantrine) is a fixed-dose combination antimalarial that kills malaria parasites by disrupting their hemoglobin metabolism and DNA replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AL unit dose age specific pre-packs TARGET	AL unit dose age specific pre-packs	Malaria Consortium, Uganda	phase 3	Artemisinin-based combination therapy (ACT)	Parasite hemoglobin metabolism; mitochondrial electron transport
Arterakin (DHA-PPQ)	Arterakin (DHA-PPQ)	National Institute of Malariology, Parasitology and Entomology, Vietnam	marketed	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum heme; parasite food vacuole
DHA/piperaquine and a SLD-PQ	DHA/piperaquine and a SLD-PQ	University of Oxford	marketed	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum and other malaria parasites (multiple targets including heme detoxification pathway)
Dihydroartemisinine-piperaquine	Dihydroartemisinine-piperaquine	Ministry of Public Health, Democratic Republic of the Congo	marketed	Artemisinin-based combination therapy (ACT)	Malaria parasite (Plasmodium species); multiple parasite targets including heme detoxification pathway
AL (Coartem)	AL (Coartem)	Centro de Investigacao em Saude de Manhica	marketed	Artemisinin-based combination therapy (ACT)	Parasite heme metabolism; hemozoin formation
DHA - PPQ group	DHA - PPQ group	National Institute of Malariology, Parasitology and Entomology, Vietnam	marketed	Artemisinin-based combination therapy (ACT)	Malaria parasite (Plasmodium spp.) — multiple targets including heme detoxification pathway and protein synthesis
AS-AQ (Carsucam)	AS-AQ (Carsucam)	Centro de Investigacao em Saude de Manhica	marketed	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum (multiple parasite targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artemisinin-based combination therapy (ACT) class)

1. University of Oxford · 6 drugs in this class
2. Centro de Investigacao em Saude de Manhica · 2 drugs in this class
3. National Institute of Malariology, Parasitology and Entomology, Vietnam · 2 drugs in this class
4. Centers for Disease Control and Prevention · 1 drug in this class
5. Oxford University Clinical Research Unit, Vietnam · 1 drug in this class
6. University Clinical Research Center, Mali · 1 drug in this class
7. Ministry of Public Health, Democratic Republic of the Congo · 1 drug in this class
8. London School of Hygiene and Tropical Medicine · 1 drug in this class
9. Malaria Consortium, Uganda · 1 drug in this class